You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Parnell Pharmaceuticals delisting from Nasdaq
Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense
Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures
MA Activity The Big Story In Mature Online Video Platform Market
Martina Cheung Backs The Quality Program
Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.
The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.
The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.